About Longboard Pharmaceutical
Longboard Pharmaceutical is a Healthcare company based in San Diego (United States) founded in 2020, and was acquired by Lundbeck in October 2024. Therapeutic solutions for rare neurological diseases are developed. Longboard Pharmaceutical has raised $56 million across 1 funding round from investors including T. Rowe Price, Lundbeck and Farallon Capital Management. The company has 50 employees. Its chief executive, as recorded, is Kevin Lind. Longboard Pharmaceutical offers products and services including GPCR Therapies. Its focus areas include Life Sciences, Rare Diseases, Drugs and CNS. Its legal entity is Longboard Pharmaceuticals, Inc. Its competitors include Biogen, Neurocrine and PTC Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Provider of therapeutic solution for treating rare neurological diseases. The company proprietary pipeline includes LP352, which is a 5-HT2C for epileptic encephalopathies; LP143 which is a cannabinoid type 2 receptor (CB2), and LP659, which is a selective S1P receptor modulator and can be used in the treatment of Epilepsies, ALS, PD, and Multiple CNS neuroinflammatory disorders.
- Headquarters San Diego, United States
- Employees 50
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website longboardpharma.com
- Social LinkedIn X
- Acquired by Lundbeck (Oct 2024)
- Legal Name Longboard Pharmaceuticals, Inc.
- Net Profit-$54.42 M (USD)-24as on Dec 31, 2023
- EBITDA-$56.76 M (USD)-27as on Dec 31, 2023
- Total Equity Funding$56M (USD)
in 1 rounds
- Latest Funding Round$56M (USD), Series C
Oct 2020
- InvestorsT. Rowe Price
& 3 more
- Employee Count50
- Acquired byLundbeck
(Oct 2024)
Products & Services of Longboard Pharmaceutical
Longboard Pharmaceutical offers a comprehensive portfolio of products and services, including GPCR Therapies.
Pipeline of neurological medicines targeting GPCR for rare diseases treatment.
Funding Insights of Longboard Pharmaceutical
Longboard Pharmaceutical has successfully raised a total of $56M through 1 strategic funding round. The most recent funding activity was a Series C round of $56 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $56M
- Total Rounds 1
- Last Round Series C — $56M
- First Round $56M
(Oct 2020)
- Investors Count 3
All 1 funding rounds of Longboard Pharmaceutical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $56M | Series C | – | Farallon Capital Management |
4 investors in total: 4 institutional.
Investors in Longboard Pharmaceutical
Longboard Pharmaceutical has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include T. Rowe Price, Lundbeck and Farallon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Late-stage life sciences investments are managed via VC and PE. | hbmpartners.com | Zug, Switzerland | ||
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
Drugs for CNS disorders are developed and advanced. | 1915 | lundbeck.com | Copenhagen, Denmark |
Investor details for Longboard Pharmaceutical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Longboard Pharmaceutical
13 people are tracked at Longboard Pharmaceutical (7 in leadership, 4 in board & advisors, 2 in team); the tracked headcount is 50.
| Name | Role | Group |
|---|---|---|
Kevin Lind | President & CEO | Leadership |
Rosa Chan | Director | Leadership |
Shakti Valdez | Director, Regulatory Affairs | Leadership |
Gus Cardenas | VP & Head, Quality Assurance | Leadership |
Steven Spector | Head, Business Development & General Counsel | Leadership |
Cheryl Rasmussen | Executive Assistant To President & CEO | Leadership |
Sophia Cacciatore | Director, Patient Advocacy | Leadership |
Casey Lynch | Board Member | Board & advisors |
Jane Tiller | Board Member | Board & advisors |
Corinne Le Goff | Board Member | Board & advisors |
Phillip Schneider | Board Member | Board & advisors |
Alyssa Ackerman | Office Manager And Executive Assistant | Team |
Kamyron Speller | Associate, Regulatory Affairs And Operations | Team |
Complete people profiles for Longboard Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Longboard Pharmaceutical
4 dated milestones of Longboard Pharmaceutical across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Longboard Pharmaceutical is founded.
- Funding First funding round of $56.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Lundbeck.
Competitors of Longboard Pharmaceutical
Longboard Pharmaceutical has 3 listed competitors in our database, 3 of them funded. They include Biogen, Neurocrine and PTC Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of Longboard Pharmaceutical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Longboard Pharmaceutical
The website of Longboard Pharmaceutical (longboardpharma.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▲ 95.3% vs previous month
Top companies in Rare Diseases
3 companies that operate in the same segment as Longboard Pharmaceutical (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Longboard Pharmaceutical
Complete news archive for Longboard Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Longboard Pharmaceutical
Longboard Pharmaceutical was founded in 2020.
Longboard Pharmaceutical is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Kevin Lind is the CEO of Longboard Pharmaceutical, as recorded in our data.
Longboard Pharmaceutical is a funded company, having raised a total of $56M across 1 funding round to date. The company's 1st funding round was a Series C of $56M, raised on Oct 2020.
Longboard Pharmaceutical has 50 employees.
Provider of therapeutic solution for treating rare neurological diseases. The company proprietary pipeline includes LP352, which is a 5-HT2C for epileptic encephalopathies; LP143 which is a cannabinoid type 2 receptor (CB2), and LP659, which is a selective S1P receptor modulator and can be used in the treatment of Epilepsies, ALS, PD, and Multiple CNS neuroinflammatory disorders.
Longboard Pharmaceutical's top competitors include PTC Therapeutics, Neurocrine and Biogen.
Longboard Pharmaceutical offers GPCR Therapies.
Longboard Pharmaceutical has 4 investors. Key investors include T. Rowe Price, Lundbeck, Farallon Capital Management, and HBM Partners.
Longboard Pharmaceutical operates through Longboard Pharmaceuticals, Inc..
Yes. Longboard Pharmaceutical was acquired by Lundbeck in October 2024.